Oxaliplatinum [Latin] en es it fr


Oxaliplatinum [Latin] Les marques, Oxaliplatinum [Latin] Analogs

Oxaliplatinum [Latin] Les marques melange

  • No information avaliable
  • Oxaliplatinum [Latin] Formule chimique


    Oxaliplatinum [Latin] RX lien


    Oxaliplatinum [Latin] FDA fiche

    Oxaliplatinum_[Latin] FDA

    Oxaliplatinum [Latin] msds (fiche de securite des materiaux)

    Oxaliplatinum_[Latin] MSDS

    Oxaliplatinum [Latin] Synthese de reference

    Aucune information disponible

    Oxaliplatinum [Latin] Poids moleculaire

    395.27 g/mol

    Oxaliplatinum [Latin] Point de fusion

    No information avaliable

    Oxaliplatinum [Latin] H2O Solubilite

    Aucune information disponible

    Oxaliplatinum [Latin] Etat


    Oxaliplatinum [Latin] LogP

    No information avaliable

    Oxaliplatinum [Latin] Formes pharmaceutiques

    Aucune information disponible

    Oxaliplatinum [Latin] Indication

    Pour le traitement des tumeurs malignes du côlon, du rectum, et de l'ovaire

    Oxaliplatinum [Latin] Pharmacologie

    L'oxaliplatine inhibe sélectivement la synthèse de l'acide désoxyribonucléique (ADN). Le contenu guanine et la cytosine est corrélée avec le degré d'oxaliplatine induit une réticulation. A des concentrations élevées de la drogue, de l'ARN cellulaire et la synthèse des protéines sont également supprimées.

    Oxaliplatinum [Latin] Absorption

    Aucune information disponible

    Oxaliplatinum [Latin] Toxicite

    Aucune information disponible

    Oxaliplatinum [Latin] Information pour les patients

    Patients and patientsí caregivers should be informed of the expected side effects of ELOXATIN, particularly its neurologic effects, both the acute, reversible effects, and the persistent neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects. Patients should be instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to cold temperature or cold objects.

    Patients must be adequately informed of the risk of low blood cell counts and instructed to contact their physician immediately should fever, particularly if associated with persistent diarrhea, or evidence of infection develop.

    Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs of dehydration, cough or breathing difficulties occur, or signs of allergic reaction appear.

    Oxaliplatinum [Latin] Organismes affectes

    Les humains et autres mammifères